<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04036149</url>
  </required_header>
  <id_info>
    <org_study_id>CT LUCIA 611P BER-401-16</org_study_id>
    <nct_id>NCT04036149</nct_id>
  </id_info>
  <brief_title>To Compare Postoperative Horizontal Position Stability of the CT LUCIA 611P and the CT ASPHINA 409MP</brief_title>
  <official_title>Prospective Clinical Trial to Compare the Postoperative Horizontal Position Stability of the CT LUCIA 611P and the CT ASPHINA 409MP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to assess the efficacy of the CT LUCIA 611P intraocular
      lens (IOL) with regard to the horizontal IOL position stability. The horizontal position
      collected at 1 month and 4 to 6 months post-operatively will be compared to the horizontal
      IOL position recorded at baseline (1 week post-operatively) as well as to the position
      stability of the reference IOL, CT ASPHINA 409MP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Actual">July 20, 2018</completion_date>
  <primary_completion_date type="Actual">July 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Horizontal position stability</measure>
    <time_frame>1 week to 4-6 months post-operatively</time_frame>
    <description>Evaluation of the horizontal position stability of the CT LUCIA 611P IOL. The horizontal position at M1 and M4-6 will be compared to the horizontal IOL position at baseline (W1) and to the position stability of the reference IOL, CT ASPHINA 409MP.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Cataract Senile</condition>
  <arm_group>
    <arm_group_label>LUCIA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT LUCIA 611P - Intraocular lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASPHINA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CT ASPHINA 409MP - Intraocular lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intraocular lens</intervention_name>
    <description>Implantation as part of cataract surgery</description>
    <arm_group_label>ASPHINA</arm_group_label>
    <arm_group_label>LUCIA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient informed of the consequences and constraints of the protocol and who has given
             his/her written informed consent;

          -  Patients of any gender, aged 50 to 90 years;

          -  Assured follow-up examinations;

          -  Healthy eyes besides clinically significant bilateral age-related cataract.

          -  Distance corrected visual acuity â‰¤ 0.3 logMAR Normal findings in the medical history
             and physical examination

          -  Calculated IOL power within the available dioptre range;

          -  Biometry measurement/cataract density compatible with the IOLMaster evaluation.

        Per operative inclusion criteria:

          -  IOL implanted in the capsular bag;

          -  The 2 IOL models (CT LUCIA 611P and CT ASPHINA 409MP) have been implanted in the 2
             eyes of one patient;

          -  No intraoperative complications; no damaged capsular bag, no intraocular haemorrhage;
             no can opener rhexis.

        Exclusion Criteria:

          -  Allergy to heparin

          -  Monophthalmic patient

          -  Ocular disorders, other than cataract, that could potentially cause future acuity loss
             to a level of 0.20 logMAR (best-corrected) or worse in either eye;

          -  Any anterior segment pathology that could significantly affect outcomes (e.g. chronic
             uveitis, iritis, corneal dystrophy, etc.);

          -  Floppy iris syndrome;

          -  Diabetic retinopathy;

          -  Traumatic cataract;

          -  Aniridia;

          -  Microphthalmus;

          -  Amblyopia;

          -  Degenerative visual disorders (e.g. macular degeneration, optic nerve atrophy, or
             retinal disorders);

          -  Patient expected to require retinal laser treatment before the end of the last
             follow-up;

          -  Previous intraocular and corneal surgery;

          -  Expected postop. astigmatism greater than 1 D;

          -  Any type of corneal disorder;

          -  Dementia;

          -  Pseudoexfoliation syndrome (PEX);

          -  Glaucoma or IOP higher than 24mmHg under ocular hypertension treatment;

          -  Any other pathology or condition presenting, according to the investigator opinion, a
             risk for the patient.

          -  Pregnancy and/or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VIROS, Hanusch Hospital, Department of Ophthalmology</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

